Printer Friendly

BONE HEALTH INC.: INDEPENDENT ANALYSIS OF ONE-ALPHA D2 TO BE COMPLETED

 TORONTO, Feb. 1 /PRNewswire/ -- Bone Health Inc. ("Bone Health") (NASDAQ: BNHWF), a Canadian corporation, hereby notifies its warrantholders that it is in the process of completing its due diligence review of the available Bone Care International, Inc. ("BCI") analysis of the final data from the clinical studies conducted at Creighton University in Omaha, Neb., regarding One-alpha D2, a drug for use in the treatment of osteoporosis. Depending upon the satisfactory completion of its due diligence review and its own final assessment of the prospects for One-alpha D2, Bone Health intends to seek an increased interest in the world rights to the drug.
 It was originally anticipated that information would be available to warrantholders by Feb. 1, 1993. Since Bone Health requires additional time in order to complete its due diligence review, it is now anticipated that additional information will be available in the near future. Following appropriate filings with securities regulatory authorities, Bone Health will distribute a complete final prospectus to all warrantholders, as permitted by law, setting forth Bone Health's intentions regarding One-alpha D2.
 Bone Health Inc., a wholly owned subsidiary of Deprenyl Research Limited, is a newly formed Canadian corporation, established to develop products including pharmaceutical prescription products for the Canadian market for the treatment of bone diseases, and in particular osteoporosis.
 -0- 2/1/93
 /CONTACT: Deborah Worobec, investor relations of Bone Health, 416-537-4372, or fax, 416-537-1653; or Jim Tolan, senior vice president of O'Connor Biro & Associates, 708-498-2284, or fax: 708-498-3144, for Bone Health
 (BNHWF)


CO: Bone Health Inc. ST: Ontario IN: MTC SU:

PS -- NY045 -- 1307 02/01/93 11:08 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 1, 1993
Words:266
Previous Article:WESTBRIDGE CAPITAL TO ACQUIRE BLOCK OF MEDICARE SUPPLEMENT POLICIES
Next Article:AMERICAN OIL AND GAS CORPORATION NAMES NEW MEMBER TO BOARD OF DIRECTORS
Topics:


Related Articles
BONE HEALTH INC. & DEPRENYL RESEARCH LIMITED ANNOUNCE SMITHKLINE BEECHAM HAS TRANSFERRED BACK TO LUNAR CORP. ALL ITS RIGHTS TO ONE-ALPHA D-2
DEPRENYL RESEARCH LTD. & BONE HEALTH INC. TO AWAIT FULL ANALYSIS OF CLINICAL TRIALS BEFORE ISSUING FINAL AMENDMENTS TO PROSPECTUS
LUNAR ANNOUNCES THAT ONE-ALPHA D2 WAS EFFECTIVE
DEPRENYL RESEARCH LTD. RECEIVES NOTIFICATION FROM LUNAR OF TAKEDA'S INTENT TO TERMINATE LICENSE AGREEMENT
BONE HEALTH INC.: INDEPENDENT ANALYSIS OF ONE-ALPHA D2 TO BE COMPLETED
BONE HEALTH INC. WARRANTS EXTENDED TO SEPT. 30, 1993
Alpha-Beta Technology Completes Acquisition of MycoTox; Announces Timeline for Final Phase III Data Review and Release
Bone Care International Announces Receipt of Notice of Patent Allowance.
Bone Care International Announces Patent Issuance.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters